Order Careers Contact Us Sign in Adaptive Biotechnologies Order Careers
Contact Us Sign in Immune Profiling Platform Platform OverviewPublications
Products & Services LIFE SCIENCES RESEARCHimmunoSEQ®CLINICAL
DIAGNOSTICSclonoSEQ®PipelineDRUG DISCOVERYCellular TherapyVaccines
PARTNERSHIPS Cancer Cellular TherapyAntigen MapBiopharma PartnershipsStrategic
Collaborators About Us Our StoryCultureCareersNewsroomContact Us Every immune
systemhas a story to tell. At Adaptive, we’re writing the next chapter of
precision health — powered by immune-driven medicine. The key is knowing how
to listen. Adaptive and Genentech, a memberof the Roche Group, partner on
thenext generation of cell therapy Learn more Read our press release *The
completion of the agreement is subject to customary closing conditions,
including clearance under the Hart-Scott-Rodino Antitrust Improvements Act,
and is expected to occur in the first quarter of 2019. OUR STORYPioneers in
immune-driven medicine Our goal is to meaningfully improve people’s lives by
learning from the wisdom of their adaptive immune systems. It’s a bold
objective that we’re uniquely built to achieve. Learn more about us A WORLD-
CLASS TEAMBecome an Adapter We’re looking for curious, passionate people to
help us write the future of immune-driven medicine. Convergent Team
Juxtaposing disciplines leads to discoveries in our field. Innovative Thinkers
Open minds explore the unimaginable. Adventure Pioneering spirit makes us
first to break new ground. Learn more OUR NEWSROOMThe latest from Adaptive
Press Release Adaptive Biotechnologies to Enter Into Worldwide Collaboration
and License Agreement with Genentech to Develop Personalized Cellular
Therapies for the Treatment of Cancer 01/04/2019 Press Release Adaptive
Biotechnologies to Present at the 37th Annual J.P. Morgan Healthcare
Conference 01/03/2019 Press Release FDA Grants De Novo Designation for
Adaptive Biotechnologies’ clonoSEQ Assay to Detect and Monitor Minimal
Residual Disease (MRD) in Patients with Multiple Myeloma and Acute
Lymphoblastic Leukemia 09/28/2018 Press Release Adaptive Biotechnologies
Announces a Collaboration With Sanofi to use Adaptive’s clonoSEQ® Assay to
Measure Minimal Residual Disease in Active and Future Isatuximab Multiple
Myeloma Trials 05/29/2018 See all news Keep up to date with Adaptive. Join our
newsletter. Corporate/Research (855) 466-8667 Diagnostics (888) 522-8988
Immune Profiling PlatformPlatform Overview Publications Products &
ServicesLIFE SCIENCES RESEARCH immunoSEQ® CLINICAL DIAGNOSTICS clonoSEQ®
Pipeline DRUG DISCOVERY Cellular Therapy Vaccines PartnershipsCancer Cellular
Therapy Antigen Map Biopharma Partnerships Strategic Collaborators About UsOur
Story Culture Careers News & Events Contact Us © Adaptive Biotechnologies. All
Rights Reserved. Terms of Use Online Privacy Policy Privacy Shield Policy
HIPAA Policy Code of Conduct Patents & Trademarks Licenses Join the Adaptive
newsletter Get news from Adaptive Biotech in your inbox. Email *First Name
Last Name Company Country * Yes, I would like to receive emails from Adaptive
Biotech. (You can unsubscribe anytime)Constant Contact Use.By submitting this
form, you are consenting to receive marketing emails from: Adaptive
Biotechnologies, 1551 Eastlake Avenue E., Suite 200, Seattle, WA, 98102. You
can revoke your consent to receive emails at any time by using the
SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced
by Constant Contact